Shilpa Medicare Bonus History: Declared 1:1 Bonus Issue on Aug 13

On Aug 13, 2025, Shilpa Medicare, through an exchange filing, announced a 1:1 bonus issue, which means eligible shareholders will receive 1 free share for every share held as of the record date.

Shilpa Medicare said in an exchange filing, “The board considered and recommended the Issue of Bonus equity shares by capitalizing a sum of Rs. 9,77,90,908 (Rupees Nine Crores SeventySeven Lakhs Ninety Thousand Nine hundred and eight only) out of the Company’s securities premium account in the ratio 1:1 i.e. 1 (One) equity share of Rs. 1/- each for every 1 (One) full paid-up equity share of Rs. 1/- each held by the Shareholders of the Company as on the Record Date, subject to the approval of Shareholders in the ensuing AGM.”

The record date for determining the entitlement of Members of the Company to receive Bonus Equity shares is Friday, 26th September, 2025

Shilpa Medicare Bonus History

Shilpa Medicare has only issued bonus shares once in the past, i.e., in 2013, in the ratio of 1:2. This means that shareholders received 1 free share for every 2 shares held.

Also Read: Key Corporate Actions for Aug 18-22, 2025: Major Dividend Updates from Coal India, RVNL, and IRCTC!

Shilpa Medicare Management Take on Q1FY26 Performance

Mr. Vishnukant Bhutada, Managing Director, said, “The first quarter of FY26 demonstrated steady progress and strong execution of our strategic priorities. Our partner successfully launched our second NDA in the U.S.—Bortezomib RTU— reinforcing our R&D-driven approach and delivering differentiated products that enhance ease of administration. Pemetrexed also gained momentum in the U.S., while Nilotinib continued to expand its presence in the EU. Additionally, we achieved a historic milestone with NorUDCA’s approval, making Shilpa the first global company approved for NAFLD treatment. These approvals, along with our robust NDA pipeline, positions us for sustained future growth. Our API division(including captive) has reported growth ~25% YoY basis.”

He further added, “New product launches, CDMO expansion, expanded capacities, and an improved product mix favoring regulated markets is expected to drive further growth for FY26. In Biologics, our strategic investment in Alveolus Bio accelerates innovation and solidifies Shilpa’s position as a global biotech enabler—bridging cutting-edge science with scalable solutions. Our Novel Biological Entities (NBEs), developed in collaboration with mAbTree and Alveolus, remain on track for Phase I human trials in FY27.

On the biosimilar front, Aflibercept has advanced to Phase III clinical trials in India, while Nivolumab has completed PCT, with Phase I trials expected to commence by the end of FY26. We have also received the initial milestone payment for Recombinant Human Albumin from Orion Corporation, and the program is progressing as planned

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.